HIV Mutations Found That Escape Key Antibody
Researchers identified viral mutations that allowed HIV to evade the antibody VRC01 in a prevention trial.
Updated on Nov. 6, 2026 in Diseases — General
Researchers identified HIV mutations that enabled escape from the antibody VRC01 in trial participants. Newer antibodies N6 and 1-18 largely retained the ability to neutralise viruses that escaped VRC01.
Why it matters
VRC01 provided about 75% protection against viruses highly sensitive to the antibody but did not prevent HIV infections overall, showing how the virus can adapt under antibody pressure. The findings could help guide future HIV prevention strategies and vaccines.
Deep sequencing of 11,730 HIV genetic sequences from 47 trial participants found resistance mutations in 8 of 26 VRC01 recipients (31%) and none in 21 placebo recipients. The mutations were rare among globally circulating HIV, and whether they weaken the virus remains unestablished.
The players
University of Cape Town
A leading South African public research university whose researchers led the study of HIV antibody escape.
University of the Witwatersrand
A major South African research university whose co-researchers contributed to the analysis of HIV sequences.
The details
The AMP trial underestimated the antibody dose needed to block HIV acquisition, giving the virus a window to escape. Researchers used deep sequencing, which detects rare variants within the viral population, to examine the sequences.
Timeline
Study published in Nature Microbiology on November 5, 2026.
Health Landscape
The AMP trials of VRC01 were the first large test of whether broadly neutralising antibodies could prevent HIV acquisition, and they showed partial protection against sensitive viruses. This new analysis explains why that protection was incomplete, as the virus adapted under antibody pressure.
The findings may shape future HIV prevention products, which could affect how people access antibody-based options. Researchers suggest combinations of antibodies may leave the virus fewer ways to escape.
The takeaway
Antibody-based HIV prevention may need combinations of antibodies to limit viral escape. Continued research into resistance will help guide the design of future prevention strategies.
Further reading
Explore more on Diseases — General for broader context on HIV prevention research.
Source note: This article includes information reported by Uct.
